Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Psychopharmacology of ADHD in pediatrics: current advances and issues

Authors Greydanus D, Nazeer A, Patel DR

Published 5 March 2009 Volume 2009:5 Pages 171—181

DOI https://doi.org/10.2147/NDT.S4075

Review by Single anonymous peer review

Peer reviewer comments 2



Donald E Greydanus, Ahsan Nazeer, Dilip R Patel

Michigan State University College of Human Medicine, Michigan State University/Kalamazoo Center for Medical Studies, Kalamazoo, MI, USA

Abstract: Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, long-acting stimulants are now available and a number of new medications are considered that are under current research.

Keywords: ADHD, methylphenidate, amphetamine, norepinephrine reuptake inhibitors, alpha-2 agonists, antidepressants

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.